Oppenheimer Reiterates Outperform on Centessa Pharmaceuticals, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Francois Brisebois has reiterated an Outperform rating on Centessa Pharmaceuticals (NASDAQ:CNTA) and maintained a $14 price target.
August 14, 2024 | 5:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Francois Brisebois has reiterated an Outperform rating on Centessa Pharmaceuticals and maintained a $14 price target.
The reiteration of an Outperform rating and the maintenance of a $14 price target by a reputable analyst can boost investor confidence in Centessa Pharmaceuticals, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100